BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33673918)

  • 1. Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy.
    Nandakumar B; Kumar SK; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Siddiqui M; Go RS; Jevremovic D; Kyle RA; Gertz MA; Rajkumar SV; Gonsalves WI
    Mayo Clin Proc; 2021 Mar; 96(3):677-687. PubMed ID: 33673918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
    Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma.
    Iriuchishima H; Ozaki S; Konishi J; Matsumoto M; Murayama K; Nakamura F; Yamamoto G; Handa H; Saitoh T; Nagura E; Shimizu K; Nojima Y; Murakami H
    Acta Haematol; 2016; 135(2):113-21. PubMed ID: 26505781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.
    Pagano L; Valentini CG; De Stefano V; Venditti A; Visani G; Petrucci MT; Candoni A; Specchia G; Visco C; Pogliani EM; Ferrara F; Galieni P; Gozzetti A; Fianchi L; De Muro M; Leone G; Musto P; Pulsoni A;
    Ann Oncol; 2011 Jul; 22(7):1628-1635. PubMed ID: 21252060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
    Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
    Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.
    Royer B; Minvielle S; Diouf M; Roussel M; Karlin L; Hulin C; Arnulf B; Macro M; Cailleres S; Brion A; Brechignac S; Belhadj K; Chretien ML; Wetterwald M; Chaleteix C; Tiab M; Leleu X; Frenzel L; Garderet L; Choquet S; Fuzibet JG; Dauriac C; Forneker LM; Benboubker L; Facon T; Moreau P; Avet-Loiseau H; Marolleau JP
    J Clin Oncol; 2016 Jun; 34(18):2125-32. PubMed ID: 27114594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience.
    Lebovic D; Zhang L; Alsina M; Nishihori T; Shain KH; Sullivan D; Ochoa-Bayona JL; Kharfan-Dabaja MA; Baz R
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):507-11. PubMed ID: 21813352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation].
    Li WJ; Wang FR; Wen L; Chen Y; Chen H; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2020 Oct; 59(10):801-806. PubMed ID: 32987483
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
    An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L
    Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances in the Diagnosis and Therapy of Primary Plasma Cell Leukemia -Review].
    Wang H; Li JY; Sun C; Zhou X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1837-1841. PubMed ID: 29262927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.
    Yu T; Xu Y; An G; Tai YT; Ho M; Li Z; Deng S; Zou D; Yu Z; Hao M; Anderson KC; Qiu L
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e652-e659. PubMed ID: 32624447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis.
    Gonsalves WI; Rajkumar SV; Go RS; Dispenzieri A; Gupta V; Singh PP; Buadi FK; Lacy MQ; Kapoor P; Dingli D; Lust JA; Zeldenrust SR; Hayman SR; Kyle RA; Gertz MA; Kumar SK
    Blood; 2014 Aug; 124(6):907-12. PubMed ID: 24957143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.
    Guan J; Ma J; Chen B
    Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation.
    Nishihori T; Abu Kar SM; Baz R; Alsina M; Harousseau JL; Kharfan-Dabaja MA
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1144-51. PubMed ID: 23416092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical perspective on plasma cell leukemia; current status and future directions.
    Tuazon SA; Holmberg LA; Nadeem O; Richardson PG
    Blood Cancer J; 2021 Feb; 11(2):23. PubMed ID: 33563906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and safety of first-line treatment with anti-CD38 monoclonal antibody-based regimen for primary plasma cell leukemia].
    Dou XL; Liu RX; Liu Y; Peng N; Wen L; Wu Y; Li Q; Zhong YP; Zhou X; Liao AJ; Jiang HN; Ma XJ; Dong HH; Fan SJ; Zhao YQ; Hu DH; Lu J
    Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):499-506. PubMed ID: 38317361
    [No Abstract]   [Full Text] [Related]  

  • 17. The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria.
    Yan W; Fan H; Xu J; Liu J; Li L; Du C; Deng S; Sui W; Hao M; Yi S; Zou D; Qiu L; Xu Y; An G
    Leuk Lymphoma; 2022 Dec; 63(12):2955-2964. PubMed ID: 35819882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary plasma cell leukemia 2.0: advances in biology and clinical management.
    Neri A; Todoerti K; Lionetti M; Simeon V; Barbieri M; Nozza F; Vona G; Pompa A; Baldini L; Musto P
    Expert Rev Hematol; 2016 Nov; 9(11):1063-1073. PubMed ID: 27759436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How I treat plasma cell leukemia.
    van de Donk NW; Lokhorst HM; Anderson KC; Richardson PG
    Blood; 2012 Sep; 120(12):2376-89. PubMed ID: 22837533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of Circulating Plasma Cells on the Prognosis of Patients with Multiple Myeloma].
    Li F; Gao YJ; Li SS; Xi YY; Yang XW; Su YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1771-1779. PubMed ID: 38071059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.